AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?

Core Viewpoint - AnaptysBio, Inc. is anticipated to report a year-over-year decline in earnings due to lower revenues, with the consensus estimate indicating a quarterly loss of $1.69 per share, reflecting an 81.7% decrease compared to the previous year [1][2]. Financial Performance Expectations - Revenues for the upcoming quarter are expected to be $3.28 million, which is a 51.8% decline from the same quarter last year [2]. - The consensus EPS estimate has been revised 0.09% lower in the last 30 days, indicating a reassessment by analysts [2]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows that the Most Accurate Estimate for AnaptysBio is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +2.76%, suggesting a bullish outlook from analysts [3][4]. - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [4]. Historical Performance - In the last reported quarter, AnaptysBio was expected to post a loss of $1.72 per share but actually reported a loss of $1.41, resulting in a positive surprise of +18.02% [7]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [7]. Investment Considerations - While an earnings beat may not solely dictate stock movement, betting on stocks expected to exceed earnings expectations can enhance the likelihood of success [8]. - AnaptysBio appears to be a compelling candidate for an earnings beat, but investors should consider other factors before making investment decisions [8].